#Israel #OncoHost #NSCLC #Binyamina #PROphetNSCLC

OncoHost to Highlight Groundbreaking Proteomics Research at ISLB 2025

OncoHost, a pioneering force in precision oncology and biomarker development, is set to present two significant posters at the 2025 International Society for Liquid Biopsy (ISLB) Annual Congress. These posters will focus on the advancements in plasma proteomics, emphasizing their potential to enhance clinical decision-making and real-time disease monitoring for patients diagnosed with non-small cell lung cancer (NSCLC).

Future of Immunotherapy Monitoring

Poster 1: Plasma Proteomics as a Systemic Monitoring Approach

Under the leadership of Dr. Michal Harel, VP of Translational Medicine at OncoHost, the first study will compare plasma proteomic signatures with circulating tumor DNA (ctDNA) in evaluating immunotherapy responses among advanced NSCLC patients. Key insights reveal three vital proteomic signatures that indicate:

• - Drug Bioavailability: Levels of soluble PD-1/PD-L1, important for understanding how well the drug is functioning in the body.
• - Immune Engagement: Metrics of T-cell activation, which reflects how effectively the immune system is reacting to the cancer treatment.
• - Tissue Damage Detection: Indicators of lung tissue impairment, crucial for early identification of non-responders.

Remarkably, this tissue damage signature has demonstrated early detection capabilities, identifying non-responders up to 6.6 months prior to traditional imaging methods. Although ctDNA tumor load showed a modest correlation with this signature, the comprehensive proteomic analysis proved to be significantly more effective in categorizing clinical response groups.

Dr. Harel stated, "These results illustrate the unmatched insight provided by plasma proteomics, encompassing the complete tumor-immune interaction in ways that ctDNA alone cannot achieve. This innovative approach holds immense potential for revolutionizing real-time treatment assessments for immunotherapy patients."

Poster 2: Predicting Immunotherapy Benefit

The second poster will be presented by Anna Manasherov, Director of Scientific Affairs at OncoHost. This research evaluates the diagnostic capacity of PROphetNSCLC®, the company's approved liquid biopsy proteomics test, in forecasting immunotherapy benefits across diverse genomic subtypes of NSCLC.

In this study, pre-treatment plasma samples from 308 NSCLC patients undergoing treatment with immune checkpoint inhibitors were meticulously analyzed. The findings indicate that a PROphet-POSITIVE result was linked to significantly improved overall survival (HR=0.39, p<0.0001), a pattern consistent across major mutation subgroups including KRAS, STK11, TP53, and KEAP1.

Notably, the predictive effectiveness of PROphetNSCLC® was established independently from the mutational status and PD-L1 expression, affirming its role as a comprehensive biomarker for predicting immunotherapy benefits. "The data strengthens the position of PROphetNSCLC® as a vital, mutation-agnostic resource for oncologists to select the best first-line treatments," remarked Ofer Sharon, CEO of OncoHost, emphasizing the groundbreaking implications of proteomics in surpassing genomic limitations to provide clinically actionable insights.

A New Era in Precision Medicine

OncoHost, headquartered in Binyamina, Israel, and Cary, North Carolina, is at the forefront of redefining precision medicine for better patient outcomes. The company’s flagship tool, PROphet®, employs plasma-based proteomic pattern analysis, using a single blood sample to facilitate informed first-line immunotherapy decisions for patients with NSCLC.

The PROphetNSCLC® test is distinguished by its clinical utility, helping physicians derive essential insights regarding optimal immunotherapy treatments tailored for each patient, directly influencing overall survival rates.

With guidance from a robust team of industry veterans and a comprehensive clinical trial encompassing over 40 sites and 1,700 patients, OncoHost's commitment to advancing precision diagnostics and biomarker innovation is clear.

For further information, visit OncoHost's website or follow them on social media platforms such as LinkedIn, X (Twitter), Facebook, and YouTube.